https://www.selleckchem.com/products/U0126.html
Few data exist on long-term growth hormone (GH) treatment in patients with Noonan syndrome (NS). To evaluate the effectiveness and safety of GH treatment in NS in clinical practice. Height gain, near-adult height (NAH), and safety were assessed in 2 complementary non-interventional studies NordiNet® IOS and ANSWER. The safety analysis included 412 patients, and the effectiveness analysis included 84 GH-treated patients (male, n = 67) with ≥4 years' height standard deviation score (HSDS) data. HSDS was determined using national reference (
Gefällt mir
Kommentar
Teilen
